THE LIMITED PRECISION OF PHASE-I TRIALS

被引：13

作者：

CHRISTIAN, MC ^{[1
]}

KORN, EL ^{[1
]}

机构：

[1] NCI,DIV CANC TREATMENT,CANC THERAPY EVALUAT PROGRAM,BIOMETR RES BRANCH,BETHESDA,MD 20892

来源：

JOURNAL OF THE NATIONAL CANCER INSTITUTE | 1994年 / 86卷 / 22期

关键词：

D O I：

10.1093/jnci/86.22.1662

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1662 / 1663

页数：2

共 9 条

[1] COLLINS JM, 1986, CANCER TREAT REP, V70, P73
[2] PHARMACOLOGICALLY GUIDED PHASE-I CLINICAL-TRIALS BASED UPON PRECLINICAL DRUG DEVELOPMENT
COLLINS, JM
GRIESHABER, CK
CHABNER, BA
[J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (16): : 1321 - 1326
[3] PHASE-I TRIAL OF THE ANTHRAPYRAZOLE CI-941 - PROSPECTIVE EVALUATION OF A PHARMACOKINETICALLY GUIDED DOSE-ESCALATION
FOSTER, BJ
NEWELL, DR
GRAHAM, MA
GUMBRELL, LA
JENNS, KE
KAYE, SB
CALVERT, AH
[J]. EUROPEAN JOURNAL OF CANCER, 1992, 28A (2-3) : 463 - 469
[4] A COMPARISON OF 2 PHASE-I TRIAL DESIGNS
KORN, EL
MIDTHUNE, D
CHEN, TT
RUBINSTEIN, LV
CHRISTIAN, MC
SIMON, RM
[J]. STATISTICS IN MEDICINE, 1994, 13 (18) : 1799 - 1806
[5] MODEL-GUIDED DETERMINATION OF MAXIMUM TOLERATED DOSE IN PHASE-I CLINICAL-TRIALS - EVIDENCE FOR INCREASED PRECISION
MICK, R
RATAIN, MJ
[J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (03) : 217 - 223
[6] PHYSICIAN-DETERMINED PATIENT RISK OF TOXIC EFFECTS - IMPACT ON ENROLLMENT AND DECISION-MAKING IN PHASE-I CANCER TRIALS
MICK, R
LANE, N
DAUGHERTY, C
RATAIN, MJ
[J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (22) : 1685 - 1693
[7] CONTINUAL REASSESSMENT METHOD - A PRACTICAL DESIGN FOR PHASE-1 CLINICAL-TRIALS IN CANCER
OQUIGLEY, J
PEPE, M
FISHER, L
[J]. BIOMETRICS, 1990, 46 (01) : 33 - 48
[8] PARADOXICAL RELATIONSHIP BETWEEN ACETYLATOR PHENOTYPE AND AMONAFIDE TOXICITY
RATAIN, MJ
MICK, R
BEREZIN, F
JANISCH, L
SCHILSKY, RL
WILLIAMS, SF
SMIDDY, J
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1991, 50 (05) : 573 - 579
[9] DESIGN AND ANALYSIS OF PHASE-I CLINICAL-TRIALS
STORER, BE
[J]. BIOMETRICS, 1989, 45 (03) : 925 - 937

← 1 →